Samsung Bioepis' First Cancer Biosimilar Approved by the FDA

Samsung Bioepis' First Cancer Biosimilar Approved by the FDA

Source: 
BioSpace
snippet: 

The U.S. Food and Drug Administration (FDA) approved South Korea’s Samsung Bioepis’ Ontruzant (trastuzumab-dttb), a biosimilar to Genentech’s Herceptin (trastuzumab).